Novan, Inc. (NASDAQ:NOVN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Novan, Inc. (NASDAQ:NOVN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02.

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers
On June 5, 2017, the stockholders of Novan, Inc. (the Company) approved an amendment to the Companys 2016 Incentive Award Plan (the Plan). The Plan was amended to increase the number of shares that may be issued under the Plan by 1,200,000 shares. The terms of the Plan are set forth under the caption Proposal No. 2Approval of Amendment to the Novan, Inc. 2016 Incentive Award Plan in the Companys definitive proxy statement for the Companys 2017 Annual Meeting of Stockholders (the Annual Meeting) filed with the Securities and Exchange Commission (the SEC) on April 17, 2017 (the Proxy Statement). As previously announced, effective June 4, 2017, G. Kelly Martin, a director of the Company, is serving as Chief Executive Officer of the Company on an interim basis. Mr. Martin is not receiving any additional compensation for his service in this role and will continue to be compensated to the Companys non-employee director compensation policy.
Item 5.07.	Submission of Matters to a Vote of Security Holders.

On June 5, 2017, the Company held the Annual Meeting. Set forth
below is a brief description of each matter considered and voted
upon at the Annual Meeting, together with the final tally of the
number of votes cast for, against or withheld, as well as the
number of abstentions and broker non-votes. A more complete
description of each matter is set forth in the Proxy Statement.

Proposal 1:Election of Directors

The stockholders elected each of the Class I directors who were
nominated to serve until the 2020 Annual Meeting of Stockholders
and until such directors successor is elected and qualified, or
until his earlier death, resignation or removal. The results of
stockholders votes on this matter were as follows:

Proposal 2:Approval of an Amendment to the Novan, Inc. 2016
Incentive Award Plan

The Amendment to the Novan, Inc. 2016 Incentive Award Plan to
increase the aggregate number of shares that may be issued under
the 2016 Plan by 1,200,000 shares was approved. The results of
stockholders votes on this matter were as follows:

Proposal 3:Ratification of Selection of Independent Registered
Public Accounting Firm

The proposal to ratify the appointment of PricewaterhouseCoopers
LLP as the Companys independent registered public accounting firm
for the fiscal year ending December 31, 2017 was approved. The
results of stockholders votes on this matter were as follows:

About Novan, Inc. (NASDAQ:NOVN)
Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company’s formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.